Please upgrade your browser

We built this website using the latest browser technologies to deliver the very best experience.

This makes the site run faster and easier to use. Unfortunately, your browser is out of date and will not support some of these technologies.

We recommend that you use a modern browser such as Google Chrome or Microsoft Edge to view this website.

Download ChromeDownload Microsoft Edge
Press release

Sensyne Health and Phesi enter joint commercial development collaboration with a leading pharmaceutical company

May 21, 2021

Oxford, U.K. and Dover, Delaware, USA 21 May 2021: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company” or the “Group”), the Clinical AI company today announces that, together with its U.S. based strategic partner Phesi Inc. (“Phesi”), the two companies have entered a joint commercial clinical development collaboration in an undisclosed disease area with a leading pharmaceutical company that is an existing client of Phesi.

The collaboration marks the first time that Sensyne and Phesi have entered a joint commercial collaboration with a pharmaceutical client since they entered into a strategic alliance in January 2021.  The development work to be undertaken involves the analysis of anonymised and de-identified real world patient data available to Sensyne with Phesi’s clinical trial data in order to optimise the design of a clinical trial programme for the client.

No financial terms have been disclosed for this collaboration.

About Sensyne – Phesi Strategic Alliance

Under the terms of the strategic alliance agreement, Sensyne and Phesi agreed to collaborate on an exclusive basis to offer synthetic clinical trial arms and clinical decision support tools combining clinical trial data with real world patient data.  Phesi’s clients include many of the world’s leading pharmaceutical and biotechnology companies.

Lord (Paul) Drayson PhD, CEO of Sensyne Health, said:

“I’m delighted to announce our first pharmaceutical collaboration with Phesi which demonstrates the benefits of combining our expertise in clinical trials, real world patient data and AI-driven analytics.”

Dr. Gen Li, Founder and President of Phesi Inc., said:

“I am looking forward to seeing our first collaboration with Sensyne come to fruition. Integrated predictive analytics is set to play a vital role in optimizing clinical development, and our work together will enable more life sciences organizations to become data-driven. Unlocking the power of data through this approach is crucial to meeting unmet medical needs around the world.”
Press release

Sensyne Health and Phesi enter joint commercial development collaboration with a leading pharmaceutical company

May 21, 2021

Oxford, U.K. and Dover, Delaware, USA 21 May 2021: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company” or the “Group”), the Clinical AI company today announces that, together with its U.S. based strategic partner Phesi Inc. (“Phesi”), the two companies have entered a joint commercial clinical development collaboration in an undisclosed disease area with a leading pharmaceutical company that is an existing client of Phesi.

The collaboration marks the first time that Sensyne and Phesi have entered a joint commercial collaboration with a pharmaceutical client since they entered into a strategic alliance in January 2021.  The development work to be undertaken involves the analysis of anonymised and de-identified real world patient data available to Sensyne with Phesi’s clinical trial data in order to optimise the design of a clinical trial programme for the client.

No financial terms have been disclosed for this collaboration.

About Sensyne – Phesi Strategic Alliance

Under the terms of the strategic alliance agreement, Sensyne and Phesi agreed to collaborate on an exclusive basis to offer synthetic clinical trial arms and clinical decision support tools combining clinical trial data with real world patient data.  Phesi’s clients include many of the world’s leading pharmaceutical and biotechnology companies.

Lord (Paul) Drayson PhD, CEO of Sensyne Health, said:

“I’m delighted to announce our first pharmaceutical collaboration with Phesi which demonstrates the benefits of combining our expertise in clinical trials, real world patient data and AI-driven analytics.”

Dr. Gen Li, Founder and President of Phesi Inc., said:

“I am looking forward to seeing our first collaboration with Sensyne come to fruition. Integrated predictive analytics is set to play a vital role in optimizing clinical development, and our work together will enable more life sciences organizations to become data-driven. Unlocking the power of data through this approach is crucial to meeting unmet medical needs around the world.”
Press release

Sensyne Health and Phesi enter joint commercial development collaboration with a leading pharmaceutical company

Sensyne Health and Phesi enter joint commercial development collaboration with a leading pharmaceutical company

May 21, 2021

Oxford, U.K. and Dover, Delaware, USA 21 May 2021: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company” or the “Group”), the Clinical AI company today announces that, together with its U.S. based strategic partner Phesi Inc. (“Phesi”), the two companies have entered a joint commercial clinical development collaboration in an undisclosed disease area with a leading pharmaceutical company that is an existing client of Phesi.

The collaboration marks the first time that Sensyne and Phesi have entered a joint commercial collaboration with a pharmaceutical client since they entered into a strategic alliance in January 2021.  The development work to be undertaken involves the analysis of anonymised and de-identified real world patient data available to Sensyne with Phesi’s clinical trial data in order to optimise the design of a clinical trial programme for the client.

No financial terms have been disclosed for this collaboration.

About Sensyne – Phesi Strategic Alliance

Under the terms of the strategic alliance agreement, Sensyne and Phesi agreed to collaborate on an exclusive basis to offer synthetic clinical trial arms and clinical decision support tools combining clinical trial data with real world patient data.  Phesi’s clients include many of the world’s leading pharmaceutical and biotechnology companies.

Lord (Paul) Drayson PhD, CEO of Sensyne Health, said:

“I’m delighted to announce our first pharmaceutical collaboration with Phesi which demonstrates the benefits of combining our expertise in clinical trials, real world patient data and AI-driven analytics.”

Dr. Gen Li, Founder and President of Phesi Inc., said:

“I am looking forward to seeing our first collaboration with Sensyne come to fruition. Integrated predictive analytics is set to play a vital role in optimizing clinical development, and our work together will enable more life sciences organizations to become data-driven. Unlocking the power of data through this approach is crucial to meeting unmet medical needs around the world.”
Press release

Sensyne Health and Phesi enter joint commercial development collaboration with a leading pharmaceutical company

Sensyne Health and Phesi enter joint commercial development collaboration with a leading pharmaceutical company

Oxford, U.K. and Dover, Delaware, USA 21 May 2021: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company” or the “Group”), the Clinical AI company today announces that, together with its U.S. based strategic partner Phesi Inc. (“Phesi”), the two companies have entered a joint commercial clinical development collaboration in an undisclosed disease area with a leading pharmaceutical company that is an existing client of Phesi.

The collaboration marks the first time that Sensyne and Phesi have entered a joint commercial collaboration with a pharmaceutical client since they entered into a strategic alliance in January 2021.  The development work to be undertaken involves the analysis of anonymised and de-identified real world patient data available to Sensyne with Phesi’s clinical trial data in order to optimise the design of a clinical trial programme for the client.

No financial terms have been disclosed for this collaboration.

About Sensyne – Phesi Strategic Alliance

Under the terms of the strategic alliance agreement, Sensyne and Phesi agreed to collaborate on an exclusive basis to offer synthetic clinical trial arms and clinical decision support tools combining clinical trial data with real world patient data.  Phesi’s clients include many of the world’s leading pharmaceutical and biotechnology companies.

Lord (Paul) Drayson PhD, CEO of Sensyne Health, said:

“I’m delighted to announce our first pharmaceutical collaboration with Phesi which demonstrates the benefits of combining our expertise in clinical trials, real world patient data and AI-driven analytics.”

Dr. Gen Li, Founder and President of Phesi Inc., said:

“I am looking forward to seeing our first collaboration with Sensyne come to fruition. Integrated predictive analytics is set to play a vital role in optimizing clinical development, and our work together will enable more life sciences organizations to become data-driven. Unlocking the power of data through this approach is crucial to meeting unmet medical needs around the world.”
Arrange to meet us
Press release

Sensyne Health and Phesi enter joint commercial development collaboration with a leading pharmaceutical company

May 21, 2021

Oxford, U.K. and Dover, Delaware, USA 21 May 2021: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company” or the “Group”), the Clinical AI company today announces that, together with its U.S. based strategic partner Phesi Inc. (“Phesi”), the two companies have entered a joint commercial clinical development collaboration in an undisclosed disease area with a leading pharmaceutical company that is an existing client of Phesi.

The collaboration marks the first time that Sensyne and Phesi have entered a joint commercial collaboration with a pharmaceutical client since they entered into a strategic alliance in January 2021.  The development work to be undertaken involves the analysis of anonymised and de-identified real world patient data available to Sensyne with Phesi’s clinical trial data in order to optimise the design of a clinical trial programme for the client.

No financial terms have been disclosed for this collaboration.

About Sensyne – Phesi Strategic Alliance

Under the terms of the strategic alliance agreement, Sensyne and Phesi agreed to collaborate on an exclusive basis to offer synthetic clinical trial arms and clinical decision support tools combining clinical trial data with real world patient data.  Phesi’s clients include many of the world’s leading pharmaceutical and biotechnology companies.

Lord (Paul) Drayson PhD, CEO of Sensyne Health, said:

“I’m delighted to announce our first pharmaceutical collaboration with Phesi which demonstrates the benefits of combining our expertise in clinical trials, real world patient data and AI-driven analytics.”

Dr. Gen Li, Founder and President of Phesi Inc., said:

“I am looking forward to seeing our first collaboration with Sensyne come to fruition. Integrated predictive analytics is set to play a vital role in optimizing clinical development, and our work together will enable more life sciences organizations to become data-driven. Unlocking the power of data through this approach is crucial to meeting unmet medical needs around the world.”